Novartis obtains additional FDA nod for Diovan

12/3/2007 | Yahoo!

The FDA has approved Novartis AG's angiotensin receptor blocker Diovan for the treatment of high blood pressure in patients ages 6 to 16. The company said it found no significant difference between the adverse experience profile for that age group and the profile for adult patients.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY